Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Journal of Clinical Psychiatry

• Publication date

  2000-03-31

• Fields of study

  Medicine, Psychology

• Identifiers
  PMID 10724129
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol

  1999cited by this paper
• 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.

  1998influential reference
• Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

  1997cited by this paper
• Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.

  1997cited by this paper
• Safety of olanzapine.

  1997cited by this paper
• Extrapyramidal symptoms in patients treated with risperidone.

  1997cited by this paper
• Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.

  1997cited by this paper
• The relationship of pharmacology to side effects.

  1997cited by this paper
• Serotonin-dopamine interaction and its relevance to schizophrenia.

  1996cited by this paper
• Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial.

  1996cited by this paper
• A reanalysis of the dopamine theory of tardive dyskinesia: the hypothesis of dopamine D1/D2 imbalance

  1996cited by this paper
• Motor and mental aspects of extrapyramidal syndromes

  1995cited by this paper
• The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.

  1995cited by this paper
• Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.

  1995cited by this paper
• Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients.

  1995cited by this paper
• Risperidone in the treatment of schizophrenia.

  1994cited by this paper
• The Nithsdale schizophrenia surveys

  1994cited by this paper
• A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.

  1993cited by this paper
• Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study.

  1993cited by this paper
• Does clozapine cause tardive dyskinesia?

  1993influential reference
• Pharmacological profile of risperidone.

  1993cited by this paper
• Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications.

  1993cited by this paper
• Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects.

  1992cited by this paper
• Prospective study of tardive dyskinesia incidence in the elderly.

  1991cited by this paper
• Integrating incidence and prevalence of tardive dyskinesia.

  1986influential reference
• Antischizophrenic drugs and brain cholinergic receptors. Affinity for muscarinic sites predicts extrapyramidal effects.

  1974cited by this paper
• Implications of amphetamine-induced stereotyped behavior as a model for tardive dyskinesias.

  1972cited by this paper
• Pseudoparkinsonism and tardive dyskinesia.

  1972cited by this paper

• Prevalence and associated factors of antipsychotic-induced extrapyramidal symptoms in the Tigray region

  2025cites this paper
• Real-World Data Mining for Signal Detection of Antipsychotics-Associated Adverse Events Using the Korea Adverse Event Reporting System (KAERS) Database

  2024cites this paper
• Recent Advances in representative small-molecule DRD2 inhibitors: Synthetic Routes and clinical applications.

  2024cites this paper
• Extrapyramidal Side Effects with Chronic Atypical Antipsychotic Can Be Predicted by Labeling Pattern of FosB and phosphoThr34-DARPP-32 in Nucleus Accumbens

  2023cites this paper
• Clozapine-Associated Agranulocytosis

  2023cites this paper
• Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019

  2022cites this paper
• Prevalence of antipsychotic-induced extrapyramidal symptoms and their association with neurocognition and social cognition in outpatients with schizophrenia in the "real-life".

  2021cites this paper
• The Prescribing Patterns of Antipsychotic Drugs and Antiparkinsonian Drugs in Elderly Patients with Dementia

  2020cites this paper
• Anticholinergic Drugs and Oral Health-related Quality of Life in Patients with Schizophrenia: A Pilot Study

  2020cites this paper
• Extra pyramidal symptoms between patients consuming typical and atypical anti-psychotics-in tertiary care centre, in eastern India

  2019cites this paper
• Olanzapine-Induced Tardive Blepharospasm: A Case Report

  2019cites this paper
• Antipsychotics for patients with pain

  2019influential citation
• Antipsychotics: Motor Side Effects

  2019cites this paper
• Interplay between adenosine receptor antagonist and cyclooxygenase inhibitor in haloperidol-induced extrapyramidal effects in mice

  2018cites this paper
• Movement Disorders After Exposure to Antipsychotic Drugs in Patients With Depressive Disorders

  2018cites this paper
• Serious mental illness

  2018cites this paper
• Tardive Dyskinesia: A Historical Perspective

  2017cites this paper
• Evaluation of the Expression Profile of Extrapyramidal Symptoms Due to Antipsychotics by Data Mining of Japanese Adverse Drug Event Report (JADER) Database.

  2017cites this paper
• Comparative Safety Profile of Single Versus Combination Antipsychotic Therapy by Using Glassgow Antipsychotic Side Effect Scale (Gass)

  2017cites this paper
• Valbenazine for Tardive Dyskinesia.

  2017cites this paper
• A multi-national comparison of antipsychotic drug use in children and adolescents, 2005–2012

  2017cites this paper
• Suicide risk and antipsychotic side effects in schizophrenia: nested case–control study

  2016cites this paper
• Predictors of New Onset Sleep Medication and Treatment Utilization Among Older Adults in the United States.

  2016cites this paper
• Job refusal among people with schizophrenia in Hospital Permai, Johor Bahru / John Chieng Kwang Chong

  2016cites this paper
• ROLE OF 5-HT2C RECEPTORS IN DYSKINESIA Review Article

  2016cites this paper
• Association of Antipsychotic Use with Extrapyramidal Symptoms: Data Mining of the Japanese National Insurance Claims Database

  2016cites this paper
• Risperidone-induced extrapyramidal side effects: is the need for anticholinergics the consequence of high plasma concentrations?

  2016cites this paper
• Drug-Induced Extrapyramidal Syndromes: Implications for Contemporary Practice.

  2016cites this paper
• Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder, Part 3: Clinical Trial Data

  2016cites this paper
• Association between Antipsychotic Use and Extrapyramidal Symptoms

  2015cites this paper
• University of Groningen Role OF 5-HT2C receptors in dyskinesia Loonen,

  2015cites this paper
• Antipsychotic treatment leading to dopamine supersensitivity persistently alters nucleus accumbens function.

  2015cites this paper
• Olanzapine Attenuates Mechanical Allodynia in a Rat Model of Partial Sciatic Nerve Ligation

  2015cites this paper
• Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: multilocus interaction in the mTOR pathway.

  2015cites this paper
• Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder: Part 1

  2015cites this paper
• Neurochemical Metabolomics Reveals Disruption to Sphingolipid Metabolism Following Chronic Haloperidol Administration

  2015cites this paper
• Tardive dyskinesia (syndrome): Current concept and modern approaches to its management

  2015cites this paper
• ROLE OF 5-HT2C RECEPTORS IN DYSKINESIA

  2015cites this paper
• A comparative review of escitalopram, paroxetine, and sertraline: are they all alike?

  2014cites this paper
• Screening of a Histone Methyltransferase Inhibitor in Animal Models of Psychiatric Illness

  2014cites this paper
• DEVELOPMENT AND VALIDATION OF A STABILITY INDICATING UV SPECTROSCOPIC METHOD FOR OLANZAPINE IN BULK AND PHARMACEUTICAL DOSAGE FORMS

  2014cites this paper
• Acute Effects of Brexpiprazole on Serotonin, Dopamine, and Norepinephrine Systems: An In Vivo Electrophysiologic Characterization

  2014cites this paper
• The catecholamine biosynthetic enzyme dopamine β-hydroxylase (DBH): first genome-wide search positions trait-determining variants acting additively in the proximal promoter.

  2014cites this paper
• The role of serotonin in the antidyskinetic effects of deep brain stimulation: focus on antipsychotic-induced motor symptoms

  2013influential citation
• Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies

  2013cites this paper
• Pain, Agitation, Delirium, and Neuromuscular Blockade: A Review of Basic Pharmacology, Assessment, and Monitoring

  2013cites this paper
• Persistent akathisia masquerading as agitated depression after use of ziprasidone in the treatment of bipolar depression

  2013cites this paper
• Intermittent versus continuous central administration of clozapine in DBA/2 mice, improvement in sensory inhibition deficits.

  2013cites this paper
• [Clinical stakes when switching from one antipsychotic to another].

  2013cites this paper
• FORMULATION AND EVALUATION OF QUETIAPINE IMMEDIATE RELEASE FILM COATED TABLETS

  2013cites this paper
• FORMULATION DESIGN AND IN - VI TRO EVALUATION OF ANTIPSYCHOTIC DRUG QUETIAPINE FUMARATE

  2013cites this paper
• Movement Disorder Emergencies of the Upper Aerodigestive Tract

  2013cites this paper
• Deep Brain Stimulation of the Subthalamic and Entopeduncular Nuclei in an Animal Model of Tardive Dyskinesia

  2013cites this paper
• Enjeux cliniques du passage d'un antipsychotique à l'autre

  2013cites this paper
• Enjeux cliniques du passage d’un antipsychotique à l’autre

  2013cites this paper
• Withdrawal Symptoms and Rebound Syndromes Associated with Switching and Discontinuing Atypical Antipsychotics: Theoretical Background and Practical Recommendations

  2013cites this paper
• incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies

  2013cites this paper
• incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies

  2013cites this paper
• Extrapyramidal motor side-effects of first- and second-generation antipsychotic drugs.

  2012cites this paper
• Paliperidone in the treatment of Schizophrenia: An overview

  2012cites this paper
• First-Episode Schizophrenia

  2012cites this paper
• The Effect of Thiothixene Antipsychotic Drug on Serum Lipid Peroxidation Level in Rat

  2012cites this paper
• Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action.

  2011cites this paper
• Risperidone and Olanzapine versus Another First Generation Antipsychotic in Patients with Schizophrenia Inadequately Responsive to First Generation Antipsychotics

  2011cites this paper
• A Retrospective (Post-Marketing) Case Series of Patients Receiving Intramuscular (IM) Olanzapine outside of Product Doses and Indications (Off-Label): Assessing Safety and Tolerability

  2011cites this paper
• Deep brain stimulation of the subthalamic or entopeduncular nucleus attenuates vacuous chewing movements in a rodent model of tardive dyskinesia.

  2011cites this paper
• Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.

  2011cites this paper
• Typical and atypical neuroleptics.

  2011cites this paper
• ffects of 5-HT 2 A and 5-HT 2 C receptor antagonists on acute and chronic yskinetic effects induced by haloperidol in rats

  2011cites this paper
• FIRST AND SECOND DERIVATIVE SPECTROPHOTOMETRIC METHODS FOR DETERMINATION OF OLANZAPINE IN PHARMACEUTICAL FORMULATION

  2010cites this paper
• Comparative efficacy of haloperidol and olanzapine in patients of schizophrenia : a 6 month follow up trial

  2010cites this paper
• A systematic review of hypothalamic–pituitary–adrenal axis function in schizophrenia: implications for mortality

  2010cites this paper
• Pharmacologyonline 2 : 971-1020 ( 2009 ) Newsletter

  2009cites this paper
• Quetiapine XR – A New Retard Formulation in the Treatment of Schizophrenia

  2009influential citation
• THE TREATMENT OF THE SCHIZOPHRENIA: AN OVERVIEW

  2009cites this paper
• Intramuscular olanzapine versus short-acting typical intramuscular antipsychotics: Comparison of real-life effectiveness in the treatment of agitation

  2009influential citation
• Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study.

  2009cites this paper
• Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease.

  2009cites this paper
• Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients

  2009cites this paper
• Use of Antipsychotics among Elderly Nursing Home Residents with Dementia in the US

  2009cites this paper
• Gene Association Studies of Schizophrenia and Tardive Dyskinesia

  2008cites this paper
• Läkemedelsbehandling och bemötande vid beteendemässiga och psykiska symtom vid demenssjukdom – BPSD

  2008influential citation
• Neuropsychiatric symptoms in Alzheimer disease and related disorders: why do treatments work in clinical practice but not in the randomized trials?

  2008cites this paper
• Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway

  2008cites this paper
• Use of antipsychotic drugs among Dutch youths between 1997 and 2005.

  2008cites this paper
• Atypical Neuroleptic Malignant Syndrome: Diagnostic Controversies and Considerations

  2008cites this paper
• ACNP White Paper: Update on Use of Antipsychotic Drugs in Elderly Persons with Dementia

  2008cites this paper
• Increased hexosaminidase activity in antipsychotic-induced extrapyramidal side effects: possible association with higher occurrence in bipolar disorder patients.

  2008cites this paper
• Typical and Atypical Antipsychotics – The Misleading Dichotomy

  2008cites this paper
• Long-term, naturalistic treatment with olanzapine, risperidone, quetiapine, or haloperidol monotherapy: 24-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study

  2008cites this paper
• Ethics of the early intervention in the treatment of schizophrenia.

  2007cites this paper
• Intramuscular Olanzapine – a UK case series of early cases

  2007cites this paper
• Tardive dyskinesia: eliminated, forgotten, or overshadowed?

  2007cites this paper
• Tardive Dyskinesia: Minimizing Risk and Improving Outcomes in Schizophrenia and Other Disorders

  2007cites this paper
• Funcionalidad, calidad de vida y uso de recursos de salud de olanzapina vs risperidona y antipsicóticos típicos: resultados de 3 años del estudio schizophrenia outpatient health outcomes (SOHO) en la región andina

  2007cites this paper
• Neurochemical and behavioral effects of m-CPP in a rat model of tardive dyskinesia.

  2007cites this paper
• Genetic association analysis of neuronal nitric oxide synthase gene polymorphism with tardive dyskinesia

  2007cites this paper
• Psychotropic Medication Effects and Side Effects

  2007cites this paper
• Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients.

  2007cites this paper
• Child and Adolescent Psychiatry and Mental Health Evaluating Movement Disorders in Pediatric Patients Receiving Risperidone: a Comparison of Spontaneous Reports and Research Criteria for Td

  2007cites this paper